Isavuconazole to prevent invasive fungal infection in immunocompromised adults

Initial experience at an academic medical centre

Christina D. Bowen, Gregory B. Tallman, Morgan Hakki, James S. Lewis

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate clinical and economic outcomes associated with the use of isavuconazole as antifungal prophylaxis in high-risk immunocompromised patients. Patients/Methods: Retrospective, single-centre cohort study of patients who received isavuconazole prophylaxis. Outcomes assessed included breakthrough IFI, early discontinuation of isavuconazole for any reason and antifungal prophylaxis prescribed at discharge. The impact on inpatient drug expenditure was evaluated using current isavuconazole and posaconazole drug costs per observed isavuconazole days of therapy (DOT) during the study period. Results: One hundred thirty-eight courses of isavuconazole prophylaxis were administered to 98 inpatients (2193 DOT). Relapsed/refractory acute myelogenous leukaemia was the indication for prophylaxis in over half (59.4%) of patients. Breakthrough IFI occurred in 8 (5.8%) courses. Suspected drug-related toxicities led to early discontinuation in 6 (4.3%) courses (five hepatotoxicity, one drug rash). At discharge, 24 (17.4%) courses lacked insurance coverage for isavuconazole. The formulary switch to isavuconazole prophylaxis resulted in an estimated mean drug cost savings of $128.25 per DOT relative to estimated posaconazole costs (P < 0.001). Conclusion: Isavuconazole may be an option for antifungal prophylaxis in high-risk immunocompromised adults and has the potential to produce significant inpatient drug cost savings. Further studies are needed to confirm the clinical efficacy and cost-effectiveness of isavuconazole in this role.

Original languageEnglish (US)
JournalMycoses
DOIs
StatePublished - Jan 1 2019

Fingerprint

Drug Costs
Inpatients
Cost Savings
isavuconazole
Invasive Fungal Infections
Formularies
Insurance Coverage
Immunocompromised Host
Health Expenditures
Exanthema
Drug-Related Side Effects and Adverse Reactions
Acute Myeloid Leukemia
Pharmaceutical Preparations
Cost-Benefit Analysis
Cohort Studies
Therapeutics
Economics
Costs and Cost Analysis
posaconazole

Keywords

  • antifungal agents
  • isavuconazole
  • systemic infection

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Isavuconazole to prevent invasive fungal infection in immunocompromised adults : Initial experience at an academic medical centre. / Bowen, Christina D.; Tallman, Gregory B.; Hakki, Morgan; Lewis, James S.

In: Mycoses, 01.01.2019.

Research output: Contribution to journalArticle

@article{64235b8a901d47288605015a6c48e236,
title = "Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre",
abstract = "Objective: To evaluate clinical and economic outcomes associated with the use of isavuconazole as antifungal prophylaxis in high-risk immunocompromised patients. Patients/Methods: Retrospective, single-centre cohort study of patients who received isavuconazole prophylaxis. Outcomes assessed included breakthrough IFI, early discontinuation of isavuconazole for any reason and antifungal prophylaxis prescribed at discharge. The impact on inpatient drug expenditure was evaluated using current isavuconazole and posaconazole drug costs per observed isavuconazole days of therapy (DOT) during the study period. Results: One hundred thirty-eight courses of isavuconazole prophylaxis were administered to 98 inpatients (2193 DOT). Relapsed/refractory acute myelogenous leukaemia was the indication for prophylaxis in over half (59.4{\%}) of patients. Breakthrough IFI occurred in 8 (5.8{\%}) courses. Suspected drug-related toxicities led to early discontinuation in 6 (4.3{\%}) courses (five hepatotoxicity, one drug rash). At discharge, 24 (17.4{\%}) courses lacked insurance coverage for isavuconazole. The formulary switch to isavuconazole prophylaxis resulted in an estimated mean drug cost savings of $128.25 per DOT relative to estimated posaconazole costs (P < 0.001). Conclusion: Isavuconazole may be an option for antifungal prophylaxis in high-risk immunocompromised adults and has the potential to produce significant inpatient drug cost savings. Further studies are needed to confirm the clinical efficacy and cost-effectiveness of isavuconazole in this role.",
keywords = "antifungal agents, isavuconazole, systemic infection",
author = "Bowen, {Christina D.} and Tallman, {Gregory B.} and Morgan Hakki and Lewis, {James S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/myc.12924",
language = "English (US)",
journal = "Mycoses",
issn = "0933-7407",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Isavuconazole to prevent invasive fungal infection in immunocompromised adults

T2 - Initial experience at an academic medical centre

AU - Bowen, Christina D.

AU - Tallman, Gregory B.

AU - Hakki, Morgan

AU - Lewis, James S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To evaluate clinical and economic outcomes associated with the use of isavuconazole as antifungal prophylaxis in high-risk immunocompromised patients. Patients/Methods: Retrospective, single-centre cohort study of patients who received isavuconazole prophylaxis. Outcomes assessed included breakthrough IFI, early discontinuation of isavuconazole for any reason and antifungal prophylaxis prescribed at discharge. The impact on inpatient drug expenditure was evaluated using current isavuconazole and posaconazole drug costs per observed isavuconazole days of therapy (DOT) during the study period. Results: One hundred thirty-eight courses of isavuconazole prophylaxis were administered to 98 inpatients (2193 DOT). Relapsed/refractory acute myelogenous leukaemia was the indication for prophylaxis in over half (59.4%) of patients. Breakthrough IFI occurred in 8 (5.8%) courses. Suspected drug-related toxicities led to early discontinuation in 6 (4.3%) courses (five hepatotoxicity, one drug rash). At discharge, 24 (17.4%) courses lacked insurance coverage for isavuconazole. The formulary switch to isavuconazole prophylaxis resulted in an estimated mean drug cost savings of $128.25 per DOT relative to estimated posaconazole costs (P < 0.001). Conclusion: Isavuconazole may be an option for antifungal prophylaxis in high-risk immunocompromised adults and has the potential to produce significant inpatient drug cost savings. Further studies are needed to confirm the clinical efficacy and cost-effectiveness of isavuconazole in this role.

AB - Objective: To evaluate clinical and economic outcomes associated with the use of isavuconazole as antifungal prophylaxis in high-risk immunocompromised patients. Patients/Methods: Retrospective, single-centre cohort study of patients who received isavuconazole prophylaxis. Outcomes assessed included breakthrough IFI, early discontinuation of isavuconazole for any reason and antifungal prophylaxis prescribed at discharge. The impact on inpatient drug expenditure was evaluated using current isavuconazole and posaconazole drug costs per observed isavuconazole days of therapy (DOT) during the study period. Results: One hundred thirty-eight courses of isavuconazole prophylaxis were administered to 98 inpatients (2193 DOT). Relapsed/refractory acute myelogenous leukaemia was the indication for prophylaxis in over half (59.4%) of patients. Breakthrough IFI occurred in 8 (5.8%) courses. Suspected drug-related toxicities led to early discontinuation in 6 (4.3%) courses (five hepatotoxicity, one drug rash). At discharge, 24 (17.4%) courses lacked insurance coverage for isavuconazole. The formulary switch to isavuconazole prophylaxis resulted in an estimated mean drug cost savings of $128.25 per DOT relative to estimated posaconazole costs (P < 0.001). Conclusion: Isavuconazole may be an option for antifungal prophylaxis in high-risk immunocompromised adults and has the potential to produce significant inpatient drug cost savings. Further studies are needed to confirm the clinical efficacy and cost-effectiveness of isavuconazole in this role.

KW - antifungal agents

KW - isavuconazole

KW - systemic infection

UR - http://www.scopus.com/inward/record.url?scp=85066117606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066117606&partnerID=8YFLogxK

U2 - 10.1111/myc.12924

DO - 10.1111/myc.12924

M3 - Article

JO - Mycoses

JF - Mycoses

SN - 0933-7407

ER -